"Toll-Like Receptor 7" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds several forms of imidazo-quinoline including the antiviral compound Imiquimod.
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 7".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 7".
This graph shows the total number of publications written about "Toll-Like Receptor 7" by people in this website by year, and whether "Toll-Like Receptor 7" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Toll-Like Receptor 7" by people in Profiles.
Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis. Front Immunol. 2019; 10:2160.
RIG-I Signaling via MAVS Is Dispensable for Survival in Lethal Influenza Infection In Vivo. Mediators Inflamm. 2018; 2018:6808934.
BANK1 Regulates IgG Production in a Lupus Model by Controlling TLR7-Dependent STAT1 Activation. PLoS One. 2016; 11(5):e0156302.
MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 2013; 9(2):e1003336.
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012 Nov; 122(11):4118-29.
Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm Bowel Dis. 2012 May; 18(5):955-67.
Toll-like receptor 7 (TLR7) modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis. 2010 Jun; 69(6):1195-9.
Genetic complementation results in augmented autoantibody responses to lupus-associated antigens. J Immunol. 2009 Sep 01; 183(5):3505-11.